Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Inclusion Criteria:

1. Patients must have signed a written informed consent form prior to any trialspecific procedures.

2. Patient aged ≥18 years old.

3. Metastatic disease (or locally advanced disease not suitable for local treatment) ofinitial tumor histologically confirmed including: lung cancer, renal cell cancer,head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkelcancer, hepatocellular carcinoma, melanoma, colorectal carcinoma with microsatelliteinstability [MSI], esophageal squamous cell carcinoma, endometrialcarcinoma,cervical cancer, gastric/gastro-oesophageal junction adenocarcinoma, basalcell carcinoma or squamous skin carcinoma.

4. Patients in partial or complete response after 6 months of standard immunotherapy (whatever the line of therapy) according to the RECIST or PERCIST v1.0 criteria (confirmed by local radiological assessment). For metastatic melanoma only patients in partial response. Patients with metastaticor advanced cancer treated by immunotherapy as maintenance therapy can be includedwithout any lesion at IO initiation. In this case, response after 6 months ofstandard immunotherapy will be evaluated by the non-appearance of a new lesion.

5. Eligible to maintain the same standard IO treatment.

6. Patient with Eastern cooperative oncology group (ECOG) performance status ≤1.

7. Patients with brain metastases are allowed, provided they are stable according tothe following definitions: treated with surgery or stereotactic radiosurgery andwithout evidence of progression prior to randomization and have no evidence of newor enlarging brain metastases.

8. Patients treated by IO previously combined with chemotherapy are allowed.

9. Patients with Tyrosine Kinase Inhibitor (TKI)-IO or pemetrexed-IO or bevacizumab-IOare allowed.

10. Evidence of post-menopausal status, or negative urinary or serum pregnancy test forpre-menopausal patients.

11. Both sexually active women of childbearing potential and males (and their femalepartners) patients must agree to use adequate contraception method for the durationof the study treatment and after completing treatment according to the most recentversion of the IO Summary of product characteristics (SmPC).

12. Patient is willing and able to comply with the protocol for the duration of thetrial including undergoing treatment and scheduled visits, and examinationsincluding follow-up.

13. Patient must be affiliated to a Social Security System.

Exclusion Criteria:

1. Metastatic melanoma in complete response.

2. Metastatic renal cell carcinoma with International Metastatic Renal Cell CarcinomaDatabase (IMDC) favourable-risk treated TKI/IO combination.

3. Hematologic malignancies (leukaemia, myeloma, lymphoma...)

4. Active infection requiring systemic therapy.

5. Patients enrolled in another therapeutic study within 30 days before the inclusionin and during MOIO study.

6. Patient unable to comply with study obligations for geographic, social, or physicalreasons, or who is unable to understand the purpose and procedures of the study.

7. Person deprived of their liberty or under protective custody or guardianship.